Eli Lilly Says FDA Approves Additional Indication For Jaypirca, Non-Covalent BTK Inhibitor, For Treatment Of Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib) as a first-line treatment for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without known 17p deletion. This approval is based on results from the BRUIN CLL-313 clinical trial, which demonstrated significant improvements in progression-free survival. Jaypirca is the first and only FDA-approved non-covalent BTK inhibitor, targeting the BTK pathway in CLL/SLL patients.